Cybin Inc.

    Cybin Inc.

    AAMEX:CYBN
    - -
    USD
    - -
    - -
    Cybin Inc.
    AMEX:CYBN
    (NYSE American)

    Recent

    price

    - -

    P/E

    ratio

    - -

    div

    yld

    - -

    ROIC.AI

    2020
    2021
    2022
    2023
    2024
    2025
    TTM
    USD
    - -
    0.33
    - -
    - -
    - -
    - -
    - -
    Revenue per Share
    - -
    -12.24
    -15.36
    -9.73
    -9.41
    -5.59
    -4.48
    Basic EPS, GAAP
    - -
    -7.32
    -10.39
    -10.4
    -8.45
    -5.11
    -4.68
    Free Cash Flow per Basic Share
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Dividend per Share
    - -
    25.7
    9.27
    2.05
    26.23
    6.18
    2.42
    Book Value per Share
    - -
    23.2
    11.63
    3.68
    25.19
    7.16
    3.26
    Tangible Book Value per Share
    - -
    3
    4
    5
    8
    20
    22
    Basic Weighted Avg Shares
    - -
    1
    - -
    - -
    - -
    - -
    - -
    Sales/Revenue/Turnover
    - -
    -3,532.87
    - -
    - -
    - -
    - -
    - -
    Operating Margin (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Depreciation Expense
    - -
    -32
    -68
    -47
    -78
    -113
    -99
    Net Income, GAAP
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Effective Tax Rate (%)
    - -
    -3,729.17
    - -
    - -
    - -
    - -
    - -
    Profit Margin (%)
    1
    62
    50
    18
    208
    145
    101
    Working Capital
    - -
    - -
    - -
    - -
    - -
    - -
    29
    LT Debt
    1
    86
    76
    48
    292
    237
    139
    Total Equity
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Invested Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Capital (%)
    - -
    -93.36
    -124.74
    -186.96
    -68.59
    -66.04
    -100
    Return on Common Equity (%)

    Capital Structure

    USD

    •

    in mil. unless spec.
    Mar'25
    Jun'26
    Sep'26
    ST Debt
    - -
    - -
    - -
    LT Borrowings
    - -
    45
    29
    LT Finance Leases
    - -
    - -
    - -
    Preferred Equity and Hybrid Capital
    - -
    - -
    - -
    Shares Outstanding
    22
    23
    26
    Market Capitalization
    183
    238
    182

    Working Capital

    USD

    •

    in mil. unless spec.
    Mar'25
    Jun'26
    Sep'26
    Total Current Assets
    166
    144
    115
    Cash, Cash Equivalents & STI
    135
    119
    84
    Accounts Receivable, Net
    6
    4
    5
    Inventories
    - -
    - -
    - -
    Total Current Liabilities
    21
    15
    13
    Payables & Accruals
    21
    15
    13
    ST Debt
    - -
    - -
    - -
    Deferred Revenue
    - -
    - -
    - -

    Growth Rates

    USD

    •

    in mil. unless spec.

    (avg. rate of change)

    10 years
    5 years
    1 year
    Total Equity
    - -
    1,257.13%
    -18.75%
    Free Cash Flow
    - -
    - -
    47.27%
    Net Income, GAAP
    - -
    - -
    44.9%
    Sales/Revenue/Turnover
    - -
    - -
    - -
    Total Cash Common Dividend
    - -
    - -
    - -

    Quarterly Revenue

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2024
    - -
    - -
    - -
    - -
    - -
    2025
    - -
    - -
    - -
    - -
    - -
    2026
    - -
    - -
    - -
    - -
    - -

    Quarterly Earnings Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2024
    -2.68
    -1.93
    -3.45
    - -
    -9.41
    2025
    -0.54
    -2.1
    -0.53
    - -
    -5.59
    2026
    -1.1
    -1.39
    - -
    - -
    - -

    Quarterly Dividends Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2024
    - -
    - -
    - -
    - -
    - -
    2025
    - -
    - -
    - -
    - -
    - -
    2026
    - -
    - -
    - -
    - -
    - -
    Similar Companies
    Business

    Company News

    Company News APIChatGPT

    • marketbeat.com

      Cybin Shareholders Weigh Helus Pharma Rebrand, Eight-Member Board

    • marketbeat.com

      Cybin Eyes Q4 Phase 3 Data for Depression Drug HLP003

    • marketbeat.com

      Cybin Eyes Q4 Phase III Depression Readout as Psychedelic Pipeline Advances

    • proactiveinvestors.com

      Johnson & Johnson’s Spravato sales growth supports psychedelic drug opportunity: Jefferies

    • proactiveinvestors.com

      CleanSpark shares surge after company secures $6.6B data center lease agreement

    • proactiveinvestors.com

      Tower Semiconductor shares jump as company announces Japan expansion to boost silicon photonics capacity

    • seekingalpha.com

      Cybin: A Speculative Bet On Their Pivotal Depression Readout

    • feeds.newsfilecorp.com

      BetterLife Pharma Announces Appointment of Doug Drysdale as Executive Chairman and Director

    • seekingalpha.com

      Cybin: Regulatory Tailwinds Unlock Asymmetric Upside (Rating Upgrade)

    • proactiveinvestors.com

      FTSE 100 Live: London stocks slide as aerospace and defence sector falls

    • proactiveinvestors.com

      Psychedelics stocks rise after Trump order expands research, access pathways

    • seekingalpha.com

      Cybin Inc. (HELP) Discusses Phase II Results for HLP004 in Generalized Anxiety Disorder Prepared Remarks Transcript

    • defenseworld.net

      Cybin (OTCMKTS:CYBN) Stock Price Up 1.2% – Here’s Why

    • businesswire.com

      Cybin Initiates At-The-Market Equity Program of up to US$100 Million

    • defenseworld.net

      Cybin (NYSEAMERICAN:CYBN) Stock Price Up 4.4% – Should You Buy?

    • businesswire.com

      Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq

    • businesswire.com

      Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq

    • defenseworld.net

      Cybin (NYSEAMERICAN:CYBN) Trading Down 8.2% – Here’s Why

    • seekingalpha.com

      Cybin Inc. (CYBN) Q2 2026 Earnings Call Transcript

    • businesswire.com

      Cybin Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights